Literature DB >> 3036038

Resection of hepatocellular carcinoma after transcatheter arterial embolization. Reevaluation of the advantages and disadvantages of preoperative embolization.

T L Hwang, M F Chen, T Y Lee, T J Chen, D Y Lin, Y F Liaw.   

Abstract

Hepatocellular carcinomas (HCCs) were resected in eight patients who had preoperative transcatheter arterial embolization (TAE) and in 25 patients without preoperative TAE. Three patients in the former group had ruptured HCCs before operation. Two of the former group and three of the latter group were found to have recurrences after a follow-up of 1 1/2 years. Although preoperative TAE resulted in significantly increased tumor necrosis, it increased the risk of gangrenous change of the gallbladder, induced adhesion of the hepatoduodenal ligament, and was not effective in reducing operative blood loss or operative time if the vessel selected for TAE was inadequate. Pathologic examination revealed tumor emboli still existing in the intrahepatic veins. Daughter nodules and capsular invasion by tumor cells were not affected by TAE. Transcatheter arterial embolization seems to be effective in controlling bleeding from ruptured HCC prior to staged resection of the tumor.

Entities:  

Mesh:

Year:  1987        PMID: 3036038     DOI: 10.1001/archsurg.1987.01400190022004

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  10 in total

Review 1.  Therapeutic modalities and prognostic factors for primary and secondary liver tumors.

Authors:  T Lehnert; G Otto; C Herfarth
Journal:  World J Surg       Date:  1995 Mar-Apr       Impact factor: 3.352

Review 2.  Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma.

Authors:  R Tung-Ping Poon; S T Fan; J Wong
Journal:  Ann Surg       Date:  2000-07       Impact factor: 12.969

3.  The potential role of postoperative hepatic artery chemotherapy in patients with high-risk hepatomas.

Authors:  T Nonami; K Isshiki; H Katoh; W Kishimoto; A Harada; A Nakao; H Takagi
Journal:  Ann Surg       Date:  1991-03       Impact factor: 12.969

4.  Hepatocellular carcinoma with adjacent organ extension: the enhancement of preoperative transcatheter arterial embolization and the results of surgical resection.

Authors:  C C Wu; W L Ho; T J Liu
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

5.  Role of preoperative transcatheter arterial chemoembolization for resectable hepatocellular carcinoma: relation between postoperative course and the pattern of tumor recurrence.

Authors:  Hiroyuki Sugo; Shunji Futagawa; Tomoe Beppu; Masaki Fukasawa; Kuniaki Kojima
Journal:  World J Surg       Date:  2003-11-05       Impact factor: 3.352

6.  Real-time quantification of AFP mRNA to assess hematogenous dissemination after transarterial chemoembolization of hepatocellular carcinoma.

Authors:  Marine Gross-Goupil; Raphaël Saffroy; Daniel Azoulay; Sophie Precetti; Jean-François Emile; Valérie Delvart; Fréderic Tindilière; Alexis Laurent; Marie-France Bellin; Henri Bismuth; Brigitte Debuire; Antoinette Lemoine
Journal:  Ann Surg       Date:  2003-08       Impact factor: 12.969

7.  Is preoperative transarterial chemoembolization needed for a resectable hepatocellular carcinoma?

Authors:  Gi-Hong Choi; Dong-Hyun Kim; Chang-Moo Kang; Kyung-Sik Kim; Jin-Sub Choi; Woo-Jung Lee; Byong-Ro Kim
Journal:  World J Surg       Date:  2007-12       Impact factor: 3.352

Review 8.  Current treatment modalities for hepatocellular carcinoma.

Authors:  D G Farmer; M H Rosove; A Shaked; R W Busuttil
Journal:  Ann Surg       Date:  1994-03       Impact factor: 12.969

9.  Postchemoembolisation syndrome--tumour necrosis or hepatocyte injury?

Authors:  S J Wigmore; D N Redhead; B N J Thomson; E J Currie; R W Parks; K K Madhavan; O J Garden
Journal:  Br J Cancer       Date:  2003-10-20       Impact factor: 7.640

10.  A prospective randomized trial of the preventive effect of pre-operative transcatheter arterial embolization against recurrence of hepatocellular carcinoma.

Authors:  S Yamasaki; H Hasegawa; H Kinoshita; M Furukawa; S Imaoka; K Takasaki; Y Kakumoto; H Saitsu; R Yamada; Y Oosaki; S Arii; E Okamoto; M Monden; M Ryu; S Kusano; T Kanematsu; K Ikeda; M Yamamoto; T Saoshiro; T Tsuzuki
Journal:  Jpn J Cancer Res       Date:  1996-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.